Kura Oncology (NASDAQ:KURA) Shares Up 8% on Analyst Upgrade

Kura Oncology, Inc. (NASDAQ:KURA) rose 8% on Friday after Wedbush raised their price target on the stock from $36.00 to $38.00. Wedbush currently has an outperform rating on the stock. Kura Oncology traded as high as $10.87 and last traded at $10.90. Approximately 858,721 shares were traded during trading, a decline of 45% from the average daily volume of 1,565,944 shares. The stock had previously closed at $10.09.

A number of other research firms also recently commented on KURA. CLSA set a $24.00 target price on Kura Oncology in a research report on Thursday, June 4th. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th. Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a report on Thursday, May 28th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $25.62.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is currently owned by insiders.

Trending Headlines about Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Kura reported a loss of $0.77 per share versus the consensus estimate of a $0.88 loss, while revenue of $20.87 million topped expectations of $20.16 million. Kura Oncology Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: KOMZIFTI® momentum improved. The drug generated $9.1 million in net product revenue, up 57% from the first quarter, with approximately 115 new patient starts, a 35% sequential increase. This provides evidence of growing commercial adoption. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management outlined meaningful future revenue potential. Kura expects $90 million–$110 million of collaboration revenue in 2027 and is targeting topline results from the KOMET-017 study in 2028, giving investors additional development and revenue milestones to track. Kura Outlines 2027 Collaboration Revenue and 2028 KOMET-017 Results
• Positive Sentiment: Wedbush raised its price target to $38 from $36 and maintained an “outperform” rating, signaling substantial potential upside based on the firm’s view of Kura’s prospects. Wedbush Raises Kura Oncology Price Target
• Neutral Sentiment: Analyst sentiment is mixed, with recent coverage highlighting conflicting views on Kura’s outlook and the latest clinical evidence. This may contribute to elevated volatility as investors assess trial data and commercialization progress. Analysts Have Conflicting Sentiments on Kura Oncology
• Negative Sentiment: Brookline Capital Markets lowered its FY2029 EPS estimate to $5.70 from $6.01. Kura also continues to report substantial losses, underscoring its dependence on product growth, collaboration revenue and successful clinical development. Kura Oncology Analyst Estimate Update

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc boosted its position in Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after buying an additional 1,284 shares during the period. Allworth Financial LP raised its stake in shares of Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Kura Oncology by 49.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after acquiring an additional 9,958 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Kura Oncology in the second quarter valued at approximately $80,000.

Kura Oncology Stock Up 8.0%

The stock has a market cap of $967.59 million, a PE ratio of -3.23 and a beta of 0.38. The business has a fifty day moving average of $10.17 and a 200-day moving average of $9.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 169.73% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.45 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.